Risk of Total Events With Icosapent Ethyl: Can We Reduce It?

J Am Coll Cardiol. 2019 Jun 11;73(22):2803-2805. doi: 10.1016/j.jacc.2019.03.492.

Authors

Christopher B Granger¹, Adam J Nelson², Neha J Pagidipati²

Affiliations

¹ Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, North Carolina. Electronic address: [email protected].
² Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, North Carolina.

PMID: 31171085
DOI: 10.1016/j.jacc.2019.03.492

No abstract available

Keywords: clinical trial; icosapent ethyl; recurrent events.

Publication types

Editorial
Comment

MeSH terms

Eicosapentaenoic Acid* / analogs & derivatives
Humans
Hypertriglyceridemia*

Substances

eicosapentaenoic acid ethyl ester
Eicosapentaenoic Acid